ACIU vs. GLPG, ZLAB, KROS, NAMS, HRMY, EVO, PTGX, SNDX, TARO, and EWTX
Should you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Galapagos (GLPG), Zai Lab (ZLAB), Keros Therapeutics (KROS), NewAmsterdam Pharma (NAMS), Harmony Biosciences (HRMY), Evotec (EVO), Protagonist Therapeutics (PTGX), Syndax Pharmaceuticals (SNDX), Taro Pharmaceutical Industries (TARO), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership, community ranking and risk.
Galapagos has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, AC Immune has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.
In the previous week, Galapagos had 1 more articles in the media than AC Immune. MarketBeat recorded 1 mentions for Galapagos and 0 mentions for AC Immune. Galapagos' average media sentiment score of 0.00 beat AC Immune's score of -0.31 indicating that AC Immune is being referred to more favorably in the news media.
Galapagos currently has a consensus price target of $34.50, indicating a potential upside of 28.92%. AC Immune has a consensus price target of $12.00, indicating a potential upside of 151.57%. Given Galapagos' stronger consensus rating and higher probable upside, analysts clearly believe AC Immune is more favorable than Galapagos.
32.5% of Galapagos shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Galapagos received 212 more outperform votes than AC Immune when rated by MarketBeat users. Likewise, 64.54% of users gave Galapagos an outperform vote while only 62.25% of users gave AC Immune an outperform vote.
AC Immune has a net margin of 0.00% compared to AC Immune's net margin of -26.25%. AC Immune's return on equity of -2.60% beat Galapagos' return on equity.
Galapagos has higher revenue and earnings than AC Immune.
Summary
AC Immune beats Galapagos on 9 of the 16 factors compared between the two stocks.
Get AC Immune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AC Immune Competitors List
Related Companies and Tools
